智飞生物(300122) - 2016 Q4 - 年度业绩预告

Financial Performance Outlook - The company expects a net profit attributable to shareholders to decline by 75% to 90% compared to the previous year, with an estimated profit range of 19.74 million to 49.35 million yuan[2]. - The estimated decline in net profit, excluding non-recurring gains and losses, is expected to be between 75% and 90%[7]. - The performance forecast is based on preliminary calculations by the company's finance department and carries a degree of uncertainty[7]. Impact of Industry Events - The decline in performance is primarily due to the impact of the "Shandong illegal vaccine case," which significantly affected vaccine sales and led to increased inventory write-down losses compared to the previous year[4]. - Regulatory changes in vaccine circulation and immunization services have caused significant short-term impacts on performance, but are expected to lead to a more optimized commercial ecosystem in the long run[6]. Sales and Market Recovery - The company has been actively promoting vaccine products and ensuring alignment between production, inventory, and market supply, despite the adverse effects of industry events[4]. - The company anticipates that the negative effects on vaccine sales will gradually dissipate, with sales beginning to recover as of the end of the reporting period[6].